Chiasma (NASDAQ:CHMA) had its target price raised by investment analysts at HC Wainwright from $10.00 to $11.00 in a research report issued on Monday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 104.46% from the stock’s current price.
A number of other brokerages have also weighed in on CHMA. Cantor Fitzgerald restated an “overweight” rating on shares of Chiasma in a research note on Tuesday, March 17th. ValuEngine upgraded shares of Chiasma from a “hold” rating to a “buy” rating in a research report on Thursday, March 5th. Zacks Investment Research downgraded shares of Chiasma from a “hold” rating to a “sell” rating in a research note on Thursday, March 19th. Finally, BidaskClub raised shares of Chiasma from a “hold” rating to a “buy” rating in a research note on Tuesday, June 23rd. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Chiasma presently has an average rating of “Buy” and a consensus target price of $11.70.
Chiasma stock opened at $5.38 on Monday. Chiasma has a 1-year low of $2.88 and a 1-year high of $9.25. The firm has a market capitalization of $222.71 million, a PE ratio of -4.89 and a beta of 1.52. The firm’s 50 day simple moving average is $6.27 and its 200 day simple moving average is $5.00.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp lifted its position in Chiasma by 3.8% in the 1st quarter. State Street Corp now owns 621,227 shares of the biotechnology company’s stock worth $2,267,000 after buying an additional 22,703 shares during the last quarter. Vivo Capital LLC bought a new position in Chiasma during the first quarter valued at approximately $4,643,000. Meeder Asset Management Inc. raised its stake in shares of Chiasma by 799.9% during the first quarter. Meeder Asset Management Inc. now owns 7,190 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 6,391 shares in the last quarter. Invesco Ltd. raised its stake in shares of Chiasma by 28.5% during the first quarter. Invesco Ltd. now owns 40,102 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 8,902 shares in the last quarter. Finally, Ikarian Capital LLC boosted its stake in shares of Chiasma by 88.1% in the 1st quarter. Ikarian Capital LLC now owns 2,075,492 shares of the biotechnology company’s stock valued at $7,576,000 after purchasing an additional 972,195 shares in the last quarter. 75.24% of the stock is currently owned by institutional investors.
Chiasma Company Profile
Chiasma, Inc, a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Featured Article: What are trading strategies for the 52-week high/low?
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.